Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

33.62
+0.96002.94%
Post-market: 33.660.0400+0.12%17:04 EDT
Volume:2.17M
Turnover:73.25M
Market Cap:4.05B
PE:-11.10
High:34.78
Open:33.11
Low:32.88
Close:32.66
Loading ...

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
22 May

CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders

MT Newswires Live
·
20 May

Eli Lilly, Rznomics Collaborate to Develop RNA-Editing Therapies for Hearing Loss Treatment

MT Newswires Live
·
16 May

Circio Secures Additional Funding for RNA Technology and Cancer Vaccine Trials

TIPRANKS
·
13 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
13 May

Eli Lilly Strikes $1B Biotech Deal with Creyon Bio to Accelerate AI-Powered RNA Drug Discovery

TIPRANKS
·
12 May

Stock Track | Avidity Biosciences (RNA) Soars 11.23% Pre-Market on HC Wainwright's Buy Rating Maintenance

Stock Track
·
12 May

Avidity Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
12 May

Avidity Biosciences price target lowered to $68 from $72 at H.C. Wainwright

TIPRANKS
·
12 May

Avidity Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Avidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate

Benzinga
·
09 May

Avidity Biosciences Inc - Strong Balance Sheet With Cash Runway Into Mid-2027

THOMSON REUTERS
·
09 May

Press Release: Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Dow Jones
·
08 May

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 May

Kathleen P. Gallagher, Chief Program Officer, Reports Disposal of Avidity Biosciences Inc. Common Shares

Reuters
·
03 May

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TIPRANKS
·
02 May

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

GlobeNewswire
·
01 May

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

GlobeNewswire
·
01 May

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Business Wire
·
23 Apr

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Dow Jones
·
22 Apr